BCM
RNAM

Bayesian Capital Management’s Avidity Biosciences RNAM Stock Holding History

Bayesian Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38,000
Closed -$1.75M – 945
2024
Q3 		$1.75M Buy
38,000
+22,700
+148% +$985K 0.2% 146
2024
Q2 		$625K Sell
15,300
-21,900
-59% -$628K 0.07% 318
2024
Q1 		$949K Buy
+37,200
New +$583K 0.09% 297
2023
Q3 		– Sell
-25,700
Closed -$285K – 943
2023
Q2 		$285K Buy
+25,700
New +$322K 0.03% 554
2023
Q1 		– Sell
-12,500
Closed -$277K – 1049
2022
Q4 		$277K Buy
+12,500
New +$186K 0.04% 511

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's RNAM Position: Q4 2024 in Review

Bayesian Capital Management sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 38,000 shares — an estimated $1.75M sold.

Bayesian Capital Management first reported a position in RNAM in Q4 2022 and held it in 5 quarters. The position peaked at $1.75M in Q3 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

  • Bayesian Capital Management reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 38,000 Avidity Biosciences shares in Q4 2024, an estimated $1.75M.
  • Bayesian Capital Management first reported a position in Avidity Biosciences in Q4 2022 and held it in 5 quarters.
  • Bayesian Capital Management's Avidity Biosciences position peaked at $1.75M in Q3 2024.
  • 236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.